2022
An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma
Hasanov E, Yeboa D, Tucker M, Swanson T, Beckham T, Rini B, Ene C, Hasanov M, Derks S, Smits M, Dudani S, Heng D, Brastianos P, Bex A, Hanalioglu S, Weinberg J, Hirsch L, Carlo M, Aizer A, Brown P, Bilen M, Chang E, Jaboin J, Brugarolas J, Choueiri T, Atkins M, McGregor B, Halasz L, Patel T, Soltys S, McDermott D, Elder J, Baskaya M, Yu J, Timmerman R, Kim M, Mut M, Markert J, Beal K, Tannir N, Samandouras G, Lang F, Giles R, Jonasch E. An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma. CA A Cancer Journal For Clinicians 2022, 72: 454-489. PMID: 35708940, DOI: 10.3322/caac.21729.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaManagement of brain metastasesBrain metastasesCell carcinomaManifestation of renal cell carcinomaResistance to systemic treatmentMultimodal treatment strategiesGuiding treatment decisionsSystemic treatmentCurrent management strategiesPoor prognosisMetastasis tumorsImmune biologyBrain metastasis tumorsRadiation treatmentTreatment strategiesInternational group of expertsCarcinomaMetastasisTreatment decisionsConsensus statementPatientsInterdisciplinary consensusUnmet patient needsLiterature review
2021
Outcomes of Stereotactic Radiosurgery and Immunotherapy in Renal Cell Carcinoma Patients With Brain Metastases
Uezono H, Nam D, Kluger HM, Sznol M, Hurwitz M, Yu JB, Chiang VL. Outcomes of Stereotactic Radiosurgery and Immunotherapy in Renal Cell Carcinoma Patients With Brain Metastases. American Journal Of Clinical Oncology 2021, 44: 495-501. PMID: 34432667, DOI: 10.1097/coc.0000000000000849.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsRCC brain metastasesBrain metastasesRenal cell carcinomaStereotactic radiosurgeryOverall survivalUse of ICIsCentral nervous system toxicityRenal cell carcinoma patientsImpact of immunotherapyLocal control outcomesMedian overall survivalCell carcinoma patientsKaplan-Meier curvesNervous system toxicityBetter median OSLog-rank testMann-Whitney U testMargin doseMedian OSNonimmunotherapy groupSRS doseCheckpoint inhibitorsImmunotherapy groupCarcinoma patients